Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99


An early feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma: first cohort in US.

Cobbs C, McClay E, Duic JP, Nabors LB, Morgan Murray D, Kesari S.

CNS Oncol. 2019 Mar;8(1):CNS30. doi: 10.2217/cns-2018-0013. Epub 2018 Dec 14.


A feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma in Australia.

Murphy M, Dowling A, Thien C, Priest E, Morgan Murray D, Kesari S.

CNS Oncol. 2019 Mar;8(1):CNS31. doi: 10.2217/cns-2018-0017. Epub 2019 Feb 7.


Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study.

Lu G, Rao M, Zhu P, Liang B, El-Nazer RT, Fonkem E, Bhattacharjee MB, Zhu JJ.

Front Neurol. 2019 Jan 31;10:42. doi: 10.3389/fneur.2019.00042. eCollection 2019.


Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery.

Sharma M, Schroeder JL, Elson P, Meola A, Barnett GH, Vogelbaum MA, Suh JH, Chao ST, Mohammadi AM, Stevens GHJ, Murphy ES, Angelov L.

J Neurosurg. 2018 Oct 1:1-11. doi: 10.3171/2018.4.JNS172909. [Epub ahead of print]


Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma.

Idbaih A, Canney M, Belin L, Desseaux C, Vignot A, Bouchoux G, Asquier N, Law-Ye B, Leclercq D, Bissery A, De Rycke Y, Trosch C, Capelle L, Sanson M, Hoang-Xuan K, Dehais C, Houillier C, Laigle-Donadey F, Mathon B, André A, Lafon C, Chapelon JY, Delattre JY, Carpentier A.

Clin Cancer Res. 2019 Mar 19. pii: clincanres.3643.2018. doi: 10.1158/1078-0432.CCR-18-3643. [Epub ahead of print]


Clinical outcomes following salvage Gamma Knife radiosurgery for recurrent glioblastoma.

Larson EW, Peterson HE, Lamoreaux WT, MacKay AR, Fairbanks RK, Call JA, Carlson JD, Ling BC, Demakas JJ, Cooke BS, Lee CM.

World J Clin Oncol. 2014 May 10;5(2):142-8. doi: 10.5306/wjco.v5.i2.142. Review.


Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.

Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, Butowski NA, Chang SM, Clarke JL, McDermott MW, Prados MD, Sloan AE, Bruce JN, Parsa AT.

Neuro Oncol. 2014 Jan;16(2):274-9. doi: 10.1093/neuonc/not203. Epub 2013 Dec 12.


Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme.

Darakchiev BJ, Albright RE, Breneman JC, Warnick RE.

J Neurosurg. 2008 Feb;108(2):236-42. doi: 10.3171/JNS/2008/108/2/0236.


Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study.

Ursu R, Carpentier A, Metellus P, Lubrano V, Laigle-Donadey F, Capelle L, Guyotat J, Langlois O, Bauchet L, Desseaux K, Tibi A, Chinot O, Lambert J, Carpentier AF.

Eur J Cancer. 2017 Mar;73:30-37. doi: 10.1016/j.ejca.2016.12.003. Epub 2017 Jan 28.


Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).

Mrugala MM, Engelhard HH, Dinh Tran D, Kew Y, Cavaliere R, Villano JL, Annenelie Bota D, Rudnick J, Love Sumrall A, Zhu JJ, Butowski N.

Semin Oncol. 2014 Oct;41 Suppl 6:S4-S13. doi: 10.1053/j.seminoncol.2014.09.010. Epub 2014 Sep 16. Erratum in: Semin Oncol. 2015 Jun;42(3):e33-43.


Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.

Gainer JL, Sheehan JP, Larner JM, Jones DR.

J Neurosurg. 2017 Feb;126(2):460-466. doi: 10.3171/2016.3.JNS152693. Epub 2016 May 13.


Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.

Field KM, Simes J, Nowak AK, Cher L, Wheeler H, Hovey EJ, Brown CS, Barnes EH, Sawkins K, Livingstone A, Freilich R, Phal PM, Fitt G; CABARET/COGNO investigators, Rosenthal MA.

Neuro Oncol. 2015 Nov;17(11):1504-13. doi: 10.1093/neuonc/nov104. Epub 2015 Jun 30.


Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.

Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY.

Neuro Oncol. 2015 Jun;17(6):862-7. doi: 10.1093/neuonc/nou350. Epub 2015 Jan 7. Erratum in: Neuro Oncol. 2015 Dec;17(12):1650.


The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.

Burri SH, Gondi V, Brown PD, Mehta MP.

Am J Clin Oncol. 2018 Feb;41(2):191-196. doi: 10.1097/COC.0000000000000395. Review.


Use of bevacizumab in recurrent glioblastoma.

Ghiaseddin A, Peters KB.

CNS Oncol. 2015;4(3):157-69. doi: 10.2217/cns.15.8. Epub 2015 Apr 23. Review.


Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.

Niranjan A, Kano H, Iyer A, Kondziolka D, Flickinger JC, Lunsford LD.

J Neurosurg. 2015 Apr;122(4):757-65. doi: 10.3171/2014.11.JNS13295. Epub 2015 Jan 16.


Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma.

Qazi MA, Vora P, Venugopal C, Adams J, Singh M, Hu A, Gorelik M, Subapanditha MK, Savage N, Yang J, Chokshi C, London M, Gont A, Bobrowski D, Grinshtein N, Brown KR, Murty NK, Nilvebrant J, Kaplan D, Moffat J, Sidhu S, Singh SK.

Cancer Res. 2018 Sep 1;78(17):5023-5037. doi: 10.1158/0008-5472.CAN-18-0267. Epub 2018 Jun 26.


Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin.

Bennett IE, Field KM, Hovens CM, Moffat BA, Rosenthal MA, Drummond K, Kaye AH, Morokoff AP.

J Neurooncol. 2017 Jan;131(2):321-329. doi: 10.1007/s11060-016-2300-0. Epub 2016 Nov 28.


Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.

van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Bain E, Ansell PJ, Holen KD, Maag D, Reardon DA.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217. doi: 10.1007/s00280-017-3451-1. Epub 2017 Oct 26.

Supplemental Content

Support Center